Fulcrum Therapeutics Inc. (NASDAQ: FULC) is 17.55% higher on its value in year-to-date trading and has touched a low of $4.37 and a high of $22.96 in the current 52-week trading range. The FULC stock was last observed hovering at around $21.97 in the last trading session, with the day’s loss setting it -2.41%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $19.56, the stock is 0.48% and 16.69% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 71910.0 and changing -10.97% at the moment leaves the stock 46.57% off its SMA200. FULC registered a gain of 15.40% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $18.74 and a 200-day simple moving average (SMA200) of $15.73.
The stock witnessed a -1.76% loss in the last 1 month and extending the period to 3 months gives it a 52.46%, and is 2.30% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.43% over the week and 8.97% over the month.
Fulcrum Therapeutics Inc. (FULC) has around 73 employees, a market worth around $459.07M and $0.80M in sales. Distance from 52-week low is 347.60% and -14.81% from its 52-week high.
Fulcrum Therapeutics Inc. (FULC) Analyst Forecasts
Fulcrum Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.79.The EPS is expected to shrink by -125.70% this year.
Fulcrum Therapeutics Inc. (FULC) Top Institutional Holders
64 institutions hold shares in Fulcrum Therapeutics Inc. (FULC), with 3.72M shares held by insiders accounting for 16.33% while institutional investors hold 80.30% of the company’s shares. The shares outstanding are 22.72M, and float is at 12.02M with Short Float at 4.61%. Institutions hold 67.19% of the Float.
The top institutional shareholder in the company is TRV GP III, LLC with over 5.96 million shares valued at $71.19 million. The investor’s holdings represent 25.51% of the FULC Shares outstanding. As of Mar 30, 2020, the second largest holder is TRV GP IV, LLC with 2.34 million shares valued at $27.98 million to account for 10.02% of the shares outstanding. The other top investors are FMR, LLC which holds 1.78 million shares representing 7.63% and valued at over $21.28 million, while Casdin Capital, LLC holds 5.17% of the shares totaling 1.21 million with a market value of $14.44 million.
Fulcrum Therapeutics Inc. (FULC) Insider Activity
A total of 43 insider transactions have happened at Fulcrum Therapeutics Inc. (FULC) in the last six months, with sales accounting for 31 and purchases happening 12 times. The most recent transaction is an insider sale by Gould Robert J. SEC filings show that Gould Robert J sold 2,500 shares of the company’s common stock on Jun 25 at a price of $20.80 per share for a total of $51992.0. Following the sale, the insider now owns 0.54 million shares.
Fulcrum Therapeutics Inc. disclosed in a document filed with the SEC on Jun 25 that Cadavid Diego (SVP Clinical Development) sold a total of 1,459 shares of the company’s common stock. The trade occurred on Jun 25 and was made at $22.00 per share for $32098.0. Following the transaction, the insider now directly holds 66785.0 shares of the FULC stock.
Still, SEC filings show that on Jun 10, Cadavid Diego (SVP Clinical Development) disposed off 401 shares at an average price of $22.00 for $8822.0. The insider now directly holds 66,785 shares of Fulcrum Therapeutics Inc. (FULC).